FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel amide derivatives of general formula [1] in any of versions (A) or (B), or its pharmaceutically acceptable salt, which possess properties of tyrosinkinase BCR-ABL inhibitor. Amide derivative of general formula [1] represents compound: 
, where according to Version (A) R1 represents any of the following groups (1)-(3): (1) -) -CH2-R11 [R11 represents saturated 4-6 member nitrogen-containing heterocyclic group, optionally containing additional nitrogen atom; saturated 5-6-member nitrogen-containing heterocyclic group, optionally containing additional nitrogen atom, which is substituted by group selected from group, consisting of oxo, -CH2-R111 (R111 represents saturated 5-member nitrogen-containing heterocyclic group), saturated 5-member nitrogen-containing heterocyclic group, aminomethyl, monoalkylaminomethyl, dialkylaminomethyl and (5-methyl-2-oxo-1,3-Dioxol-4-yl)methyl, and in addition, can be substituted by 1 or 2 similar or different substituents, selected from group, consisting of (C1-C4)alkyl, (C1-C4 alkoxycarbonyl, halogen, halogen(C1-C4)alkyl, hydroxy(C1-C4)alkyl, amino, carbamoyl], (2) -O-R12 [R12 represents saturated 4-6-member nitrogen-containing heterocyclic group]; and (3) - CH=R13 [R13 represents saturated 4-6-member nitrogen-containing heterocyclic group, which can contain additional nitrogen atom, and which can be substituted by 1-3 similar or different substituents, selected from group, consisting of oxo, (C1-C4)alkyl]; R2 represents (C1-C4)alkyl, halogen, halogen(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy and carbamoyl; R3 represents hydrogen, halogen; Het1 represents any of groups with the following chemical formulae [4] and [6]: 
[4] 
[6] 
[19] 
[10] Het2 represents pyridyl or pyrimidinyl. According to Version (B) R1 represents -CH2-R14 [R14 represents saturated 4-6-member nitrogen-containing heterocyclic group, optionally containing additional nitrogen atom; saturated 5-6-member nitrogen-containing heterocyclic group, which can be substituted by 1-3 similar groups, selected from (C1-C4)alkyl] R2 represents (C1-C4)alkyl, halogen, halogen(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxy (C1-C4)alkyl, (C1-C4)alkoxycarbonyl, (C1-C4)acyl, amino, mono(C1-C4)alkylamino, di(C1-C4)alkylamino, nitro, carbamoyl, mono(C1-C4)alkylcarbamoyl, di(C1-C4)alkylcarbamoyl or cyano; R3 represents hydrogen or halogen; Het1 represents any of groups with the following chemical formulas [9] and [10], Het2 represents pyridyl.
EFFECT: invention can be applied for treatment of chronic myeloleukosis, acute lymphoblastic leukosis and acute myeloblastic leukosis.
6 cl, 89 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AMIDE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC AGENTS BASED ON THEREOF | 2003 |
|
RU2315043C2 |
| N-PHENYL-2-PYRIMIDINE DERIVATIVES | 2003 |
|
RU2370493C2 |
| THIENO[3,2-d]PYRIMIDINE DERIVATIVES, POSSESSING INHIBITING ACTION WITH RESPECT TO PROTEINKINASE | 2011 |
|
RU2524210C2 |
| METHODS AND INTERMEDIATE COMPOUNDS FOR PREPARING IMATINIB, OPTIONALLY RADIOLABELLED | 2006 |
|
RU2440999C2 |
| TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | 2009 |
|
RU2561104C2 |
| PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | 2014 |
|
RU2656591C2 |
| NEW DERIVATIVE OF PYRIDO [3,4-d] PYRIMIDINE-8-ONE WITH PROTEIN KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, CONTAINING ABOVE DERIVATIVE | 2020 |
|
RU2780168C1 |
| POLYMORPHOUS FORM OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITOR AND METHOD OF ITS OBTAINING | 2012 |
|
RU2491286C1 |
| NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2598852C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2401265C2 |
